Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, has completed the first dose in patients in Phase II clinical trial of INS018_055, which marks the world’s first anti-fibrotic small molecule inhibitor discovered and designed using generative AI, initiating Phase II clinical trials for further evaluation. With the potential to combat fibrosis and inflammation, INS018_055 holds promise as a viable treatment option for patients worldwide.
The study is a randomised, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 12-week oral INS018_055 dosage in subjects with IPF divided into 4 parallel cohorts. To further evaluate the candidate in wider populations, the company plans to recruit 60 subjects with IPF at about 40 sites in both the U.S and China.
Previously, INS018_055 received positive topline data in Phase I in early 2023. In Phase I trials carried out in New Zealand and China, INS018_055 was tested in 78 and 48 healthy subjects, divided into cohorts focusing on a single ascending dose (SAD) study and multiple ascending dose (MAD) study. The international multi-sites Phase I studies yielded consistent results, demonstrating favourable safety, tolerability, and pharmacokinetics (PK) profiles of INS018_055, supporting the initiation of the Phase II study.
“With demonstrated potential against both fibrosis and inflammation, INS018_055 could offer another option for patients worldwide,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “The achievement of the first dose for INS018_055 in Phase II clinical trial is not only an important step for Insilico but also a milestone for AI-driven drug discovery and development. Together, we are expecting more achievements powered by AI for global unmet medical needs.”
“When we started developing generative AI for drug discovery, I never expected to see the clinical and preclinical results we have today,” said Alex Zhavoronkov, PhD, Founder and co-CEO of Insilico Medicine. “Initiating Phase II trials with this novel inhibitor for IPF represents a major milestone for deep generative reinforcement learning in drug discovery. We will explore the efficacy for patients of AI-discovered and designed treatments in clinical trials, which is a true validation of our generative AI platform. We are eager to continue to advance this potentially first-in-class therapy forward to help patients in need and show the value of generative AI in drug discovery and development.”
Insilico Medicine launched its target discovery AI platform PandaOmics, generative chemistry AI platform Chemistry42, and clinical trial analysis platform inClinico commercially to enable the biotechnology and the pharmaceutical industry to utilise the advanced generative AI tools to power their internal research and development. Powered by generative AI, Insilico is delivering breakthroughs for healthcare in multiple disease areas. Since 2021, Insilico has nominated and announced 12 preclinical candidates in its comprehensive portfolio of over 30 assets and has advanced 3 of them to the clinical stage.
The Company has benefited from a strong technology partnership with NVIDIA. “When we started, there were hundreds of companies claiming to be using AI for drug discovery,” said Alex Zhavoronkov, PhD, Founder and co-CEO of Insilico Medicine. “But Insilico was started as a deep learning pureplay at NVIDIA GTC. We were one of the first to get the DevBox, test the latest hardware early, and now work on the DGX Cloud. I personally treat Jensen Huang as a role model CEO and integrate NVIDIA’s best business and technology practices at Insilico. We made a bet on generative AI early, worked hard, and now we can tangibly demonstrate substantial R&D performance boosts and real clinical-stage drugs imagined by AI with many desired properties confirmed by hundreds of experiments”
